Workflow
植入式给药装置
icon
Search documents
《全球及中国植入式给药装置市场:规模扩张与增长前景》
QYResearch· 2025-05-28 09:30
Core Viewpoint - The article discusses the growth and trends in the global and Chinese implantable drug delivery device market, highlighting the increasing demand driven by chronic diseases and advancements in medical technology [1][5][7]. Market Overview - The global implantable drug delivery device market is projected to reach $565 million in sales by 2024 and $692 million by 2031, with a compound annual growth rate (CAGR) of 2.98% from 2025 to 2031 [1]. - The Chinese market is expected to grow from $9 million in 2024 to $13.4 million by 2031, representing approximately 16% and 1.93% of the global market, respectively [4]. Competitive Landscape - The market is highly concentrated, with the top five companies (BD, B. Braun, AngioDynamics, ICU Medical, and Linhua Medical) holding 83.54% of the market share in 2024 [4]. - BD leads the industry with innovative infusion solutions and a global supply chain, while other companies focus on specific market segments to meet diverse clinical needs [4]. Growth Drivers - The increasing prevalence of chronic diseases such as cancer and diabetes is driving the demand for long-term intravenous infusion, making implantable drug delivery devices more appealing due to their advantages in reducing repeated punctures and vascular damage [5]. - Advances in medical technology, including safer anti-infection coatings and smart monitoring features, enhance device reliability and patient experience [5]. - Improved healthcare systems and expanded insurance coverage are reducing the financial burden on patients, facilitating market penetration [5]. Challenges - High costs associated with implantable drug delivery devices, including surgical and post-care expenses, limit their adoption in developing countries [5]. - Despite technological advancements, risks of complications such as infections and thrombosis remain, requiring skilled operation by healthcare professionals [5]. - Regulatory complexities and varying standards across countries prolong product approval timelines, impacting market entry [5]. Future Trends - The market is expected to evolve towards technological innovation and smart solutions, with advancements in biocompatible materials and remote monitoring technologies enhancing safety and patient comfort [6][7]. - The demand for personalized medication plans is increasing, pushing products towards more efficient, safer, and smarter designs [7]. - The competition will intensify, focusing on product innovation, market expansion, and cost control, particularly in high-value areas like anti-infection technology and smart infusion [6][7].
数千万融资!给药装置创新企业完成天使轮
思宇MedTech· 2025-04-11 03:46
报名:首届全球眼科大会 | 议程更新 报名:首届全球骨科大会 | 议程更新 报名:首届全球心血管大会 | 奖项申报 合作伙伴征集:2025全球手术机器人大会 近日,中国植入式给药装置领域的创新先锋—— 炜璨医疗 宣布 完成数千万元天使轮融资 。本轮融资由元禾 原点和诺庾资本联合领投,南京江北科投跟投。 此前,公司还获得了华创资本 数千万元种子轮 融资。 本轮 资金将主要用于加快第一代产品上市步伐、加速新一代产品研发以及推动颠覆性创新产品的项目落地。 # 关于炜璨医疗 炜璨医疗成立于2023年4月11日,总部位于江苏省南京市。公司是一家 专注于传统肿瘤介入通路与植入式智 能化介入产品 的创新型医疗器械公司, 聚焦介入式医疗器械与智能化技术赛道 。公司早期采用国际国内成熟 技术储备,依靠企业自研团队开发静脉、动脉、镇痛、腹腔、透析通路等各种应用场景下的植入式给药装置系 列产品,其中大量产品为国内外首创。 产品与技术 炜璨医疗的产品线主要围绕植入式给药装置展开,其核心产品包括 静脉、动脉、镇痛、腹腔、透析通路等各 种应用场景下的植入式给药装置 。公司采用校企联合研发模式,与创新型新材料团队合作,打磨了可以国产 替代 ...